Wells Fargo & Company Nurix Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NRIX
# of Institutions
185Shares Held
67.3MCall Options Held
40.9KPut Options Held
106K-
Black Rock Inc. New York, NY6.82MShares$186 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.42MShares$120 Million6.02% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.99MShares$109 Million2.73% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$106 Million1.08% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.63MShares$98.7 Million0.0% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $1.28B
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...